The Insulin Cap: What the $35 Rule Actually Covers (2026)

The "$35 insulin cap" is one of the most talked-about drug-cost policies in years, but there is real confusion about who it covers and what it means at the pharmacy. This explainer lays out exactly what the rule does, where it applies, and what to do if it does not apply to you.

The details trace to the HHS summary of the Inflation Reduction Act. Prices come from our catalog cross-checked against the CMS NADAC file. For a full price breakdown by insulin type, see our insulin prices guide.

Where the cap comes from

The Inflation Reduction Act established that Medicare beneficiaries pay no more than $35 per month for each covered insulin. This applies to both Part D (pharmacy) insulins and Part B insulins used with durable medical equipment like insulin pumps. It took effect through 2023 and remains in force in 2026.

Who it covers, and who it doesn't

• Covered: people with Medicare Part D or Part B who use insulin.
• Not automatically covered by the federal law: people with commercial insurance or no insurance.
• Often covered by voluntary manufacturer caps: many commercial and cash patients, via savings programs from Lilly, Novo Nordisk, and Sanofi.

So the federal cap is a Medicare rule, but the major insulin makers voluntarily extended $35-style caps or savings programs to many other patients. Eligibility for those voluntary programs varies, so it is worth checking the manufacturer's site for your specific insulin.

"Per prescription" matters

The cap is $35 per covered insulin prescription per month, not $35 total for all your diabetes supplies. If you use two different insulins, you may see two $35 charges. Understanding this helps you predict your monthly cost and spot billing errors.

If the cap doesn't apply to you

If you are uninsured or your plan or insulin is not covered by a cap, the next-best savings are authorized generics and biosimilars, which contain the same insulin at a much lower price. Generic insulin lispro runs about $79 versus $332 for brand Humalog; generic glargine about $68 versus $284 for Lantus. Ask specifically for the authorized generic and compare pharmacies.

How to actually claim the cap at the pharmacy

The cap is not always applied automatically without the right coverage on file, so a little diligence protects you. If you have Medicare Part D or Part B and use insulin, your covered insulin should ring up at $35 or less per month per prescription, if it does not, that is a signal to ask the pharmacist to check how the claim was processed, since a billing or coverage error can produce an incorrect charge. If you have commercial insurance, the $35 price usually comes from a manufacturer copay card rather than the federal law, and you generally have to enroll in that card and present it at the pharmacy for the discount to apply. Keep the card information with your other pharmacy details so it is not forgotten at pickup.

Because the cap is per prescription, also make sure each of your insulins is being processed correctly if you use more than one. It is worth confirming the price on the first fill after any change in plan, insulin, or pharmacy, since that is when errors are most likely to slip through.

Why the cap doesn't fix everything

The $35 cap is a major relief for the people it covers, but it is narrower than headlines suggest. It is fundamentally a Medicare provision, so uninsured patients and many with commercial coverage depend on the manufacturers' voluntary programs, which can change and which carry their own eligibility rules. The cap also does not lower the underlying list price of insulin, it shifts who absorbs the cost, so the broader affordability problem persists for anyone outside its reach. That is why the authorized generics and biosimilars remain so important: they attack the actual price rather than capping a copay, and they are available to anyone regardless of insurance status. For a cash payer, asking for the authorized generic is often the single most reliable way to cut insulin cost, cap or no cap.

In short, treat the cap as one tool among several. If it applies to you, use it; if it does not, the cheaper versions of the same insulin are your fallback, and comparing pharmacies ensures you pay the least for whichever route fits.

The bottom line on the cap

The $35 insulin cap is a real and meaningful protection, but it is important to know its edges: it is a Medicare rule at its core, it applies per prescription rather than per visit, and it does not automatically cover everyone. If you are on Medicare, confirm your insulin is ringing up at the capped price. If you have commercial insurance, enroll in the manufacturer copay card that provides a similar price. And if neither applies, fall back to the authorized generics and biosimilars and compare pharmacies. With those steps, most people can bring insulin costs down substantially regardless of which category they fall into.

How BetterBuyRx helps

BetterBuyRx shows verified cash prices for each insulin and its authorized generic across pharmacies, so if the cap does not cover you, you can still find the cheapest version. Compare Humalog, NovoLog, and Lantus, or read our insulin prices guide.